Key highlights
- Interim data cutoff was July 29, 2025.
- 100% response rate in 1L left-sided mCRC (n=8).
- 62% response rate in 2L left- and right-sided mCRC (n=13).
- Data presented on October 24, 2025, at AACR-NCI-EORTC conference.
Interim Data Overview
Merus N.V. announced interim clinical data from a phase 2 trial of petosemtamab, a bispecific antibody, in combination with FOLFOX/FOLFIRI for metastatic colorectal cancer (mCRC). The data cutoff was July 29, 2025.
Response Rates
The trial showed a 100% response rate in first-line (1L) left-sided mCRC patients (n=8) and a 62% response rate in second-line (2L) left- and right-sided mCRC patients (n=13).
Conference Presentation
These findings were presented by Dr. Moh’d Khushman at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025.
